Chemotherapy for advanced pancreatic cancer (Q33187541)

23 July 2017

1 reference

title

Chemotherapy for advanced pancreatic cancer (English)

1 reference

23 July 2017

1 reference

1 reference

Daniel G Haller

1

1 reference

PubMed ID

12826247

23 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

International Journal of Radiation Oncology Biology Physics

23 July 2017

1 reference

23 July 2017

56

1 reference

23 July 2017

16-23

1 reference

23 July 2017

4 Suppl

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

1 reference

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900448-6

7 January 2021

10.1016/S0360-3016(03)00448-6

Identifiers

DOI

1 reference

23 July 2017

1 reference

PubMed ID

12826247